Druck Icon

Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures

Insider information pursuant to Article 17 MAR

Berlin, 17 January 2023. According to preliminary, unaudited figures, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) is expected to achieve a Group net profit of roughly EUR 30 million and Group sales of around EUR 225 million for the 2022 financial year. The result is thus expected to be around 10% higher than the figures forecasted in July 2022 of around EUR 27 million for Group net profit and around EUR 200 million for Group sales.

The audited full annual financial statements for the FY 2022 are scheduled to be published on 30 March 2023.

For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

17-Jan-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
13125 Berlin
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1536993

End of Announcement EQS News Service


show this